The treatment of tumors with oncolytic viruses is a promising approach in tumor therapy. Disadvantageously, the immune system attacks these oncolytic viruses, like any other virus-caused disease, by means of antibodies that are capable of recognizing defined structures of the viral particle which finally leads to the inactivation of the virus. Since antiviral antibodies actually represent highly effective defense vehicles, we are aiming to to convert this potential into an anti-tumor weapon. In our group we are developing recombinant Adapter proteins, that attract and bind these antibodies, while turning them away from the oncolytic virus, and also selectively redirect them towards tumor cells. As a consequence of this antibody labelling Killer cells can now effectively recognize and fight the tumor cells. In several experimental tumor models we were able to confirm the proof-of-principle of this therapeutic strategy.

Here you can get further information.